Index librorum: the cited literature

How this index is composed

The references catalogued below are the primary publications and the U.S. FDA label that the rest of the site cites. Each entry lists author, title, journal, year, and digital object identifier where available, with a link to the canonical PubMed, PubMed Central, publisher, or FDA-hosted location of the source. Where a finding is reported in more than one publication, the index lists the primary source — the original Phase 3 trial report rather than a downstream review or commentary. The exception is the narrative pharmacological review ^[17], which is cited where pooled efficacy figures across SURPASS 1 through 5 are reported.

No claim on this site is sourced to a non-primary or secondary commentary. No claim is sourced to a press release. Numerical figures cited inline — half-lives, HbA1c reductions, weight reductions, AHI reductions, MACE event rates — are taken from the figures reported in the cited primary publications. Where the figure was reported across a range of doses (5, 10, 15 mg), the full range is reproduced rather than a single arm cherry-picked for emphasis.

Index librorum

The numbered list follows. Each citation is provided in full form below, with a hanging mono DOI and a link to the canonical source.

Provenance and editorial reach

Sources are drawn from the New England Journal of Medicine (eight entries), The Lancet (one entry), JAMA (one entry), Diabetes Care (one entry), Diabetes Therapy (one entry), Diabetes, Obesity and Metabolism (three entries), Molecular Metabolism (one entry), Proceedings of the National Academy of Sciences (one entry), JCI Insight (one entry), CPT: Pharmacometrics & Systems Pharmacology (one entry), and the U.S. Food and Drug Administration (one entry, the approved label). A single real-world retrospective cohort archived through PubMed Central completes the index. Phase 3 randomized controlled trials are weighted most heavily across the site; mechanism and pharmacokinetics are sourced to the corresponding peer-reviewed publications.

The site claims no other affiliations. No editorial relationship with any pharmaceutical manufacturer, telehealth platform, or clinic underwrites this index — and none is permitted under the Phase 1 editorial standards of the publisher.